NeurAxis, Inc. - NRXS
About Gravity Analytica
Recent News
- 06.10.2025 - NeurAxis Achieves Critical Milestone; Secures Key Academic Society Guidelines Recommendation for Treatment of Functional Abdominal Pain (FAP) in IBS
- 05.27.2025 - NeurAxis to Participate in the Lytham Partners Spring 2025 Investor Conference on May 29, 2025
- 05.27.2025 - NeurAxis to Participate in the Lytham Partners Spring 2025 Investor Conference on May 29, 2025
- 05.22.2025 - NeurAxis Announces Closing of $5.0 Million Registered Direct Offering
- 05.22.2025 - NeurAxis Announces Closing of $5.0 Million Registered Direct Offering
- 05.21.2025 - NeurAxis Announces $5.0 Million Registered Direct Offering
- 05.21.2025 - NeurAxis Announces $5.0 Million Registered Direct Offering
- 05.20.2025 - NeurAxis Awarded First Ever FDA Clearance for the Treatment of Pediatric FAP/Functional Dyspepsia (FD) and Associated Nausea Symptoms
- 05.20.2025 - NeurAxis Awarded First Ever FDA Clearance for the Treatment of Pediatric FAP/Functional Dyspepsia (FD) and Associated Nausea Symptoms
- 05.12.2025 - NeurAxis Reports Strong First Quarter 2025 Financial Results Driven by a 39% Growth in Revenues